Drug Type Interleukins |
Synonyms rHuIL-12 (Libo Pharma) |
Target |
Action modulators |
Mechanism IL-12R modulators(Interleukin-12 receptor modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cutaneous T-Cell Lymphoma | Preclinical | United States | 15 Jul 2024 |